Trials / Active Not Recruiting
Active Not RecruitingNCT04167917
NTX-301 in MDS/AML
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NTX-301 | oral hypomethylating agent |
Timeline
- Start date
- 2021-01-06
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2019-11-19
- Last updated
- 2025-09-24
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04167917. Inclusion in this directory is not an endorsement.